Inclusion criteria:
Patients who are between 20 and 60 years old
Diagnosed with gastroesophageal reflux (GERD) based on clinical symptoms (having reflux at least twice a week), diagnostic endoscopy (esophagogastroduodenoscopy) and the Los Angeles classification (grades A to D)
Not taking PPI for at least 1 week before entering the study
Exclusion criteria:
Patients who are infected with H. pylori in the initial diagnostic examinations and before the intervention, based on stomach biopsy or stool test
Patients with coagulation disorders or GI bleeding
Patients who have a history of upper GI surgery or suffer from other digestive diseases such as irritable bowel syndrome, peptic ulcer, obstructive disease, etc
Patients with Zollinger-Ellison syndrome, primary motility disorders, Barrett's esophagus, esophageal stricture, and any severe disease with reflux and malignancy of the upper gastrointestinal tract, as well as pregnant or lactating women
Patients who take PPIs from 28 days before diagnostic endoscopy or H2 receptor antagonists from 14 days before diagnostic endoscopy
Patients who take NSAIDs or other drugs that may interfere with the interpretation of the study result. (diazepam, quinidine, Dilantin, warfarin, anticholinergics, prostaglandin analogs, or sucralfate)
Patients with chronic kidney, lung, and liver diseases and ...
Patients who have a history of sensitivity to pantoprazole or seasonal allergies or asthma
Patients who consume alcohol or drugs